The purpose of the study was to determine the toxicities and effectiveness of a novel preparative regimen of busulfan (Bu) 14 mg/kg, etoposide 50 or 60 mg/kg, and cyclophosphamide (Cy) 120 mg/kg in non-Hodgkin's lymphoma (NHL) and to analyze results using doses based on different body weight parameters and the two different etoposide doses. Three hundred and eightytwo patients aged 16 to 72 underwent first autologous transplantation with mobilized peripheral blood progenitor cells between August 1992 and December 1998 at either of two transplant centers. Mucositis was the most common toxicity. Hepatic toxicity was the most common life-threatening toxicity; severe hepatic VOD occurred in 11 patients (2.9%). Ten patients (2.6%) died from treatment-related toxicity. The 3-year progressionfree survival (PFS) for the entire group was 46.9% (95% CI, 40.5-53.3%). Elevated LDH, resistance to chemotherapy, and intermediate/aggressive histology were significant adverse prognostic factors. For patients in sensitive first relapse PFS was 47.0% (95% CI, 37-57%). Neither etoposide dose nor body weight parameter utilized significantly affected outcome. In conclusion, the novel preparative regimen of Bu, etoposide and Cy results in a low incidence of treatment-related mortality and is effective in the treatment of patients with NHL. Bone Marrow Transplantation (2000) 25, 1243-1248.
and/or less sensitive disease 1, [3] [4] [5] and in individuals with low-grade lymphoma. [6] [7] [8] [9] [10] [11] [12] The appropriate role of high-dose chemotherapy and autologous transplantation in these settings is less clear. The incidence of transplant-related mortality (approximately 10% and higher in many studies 1, 3, 5, 8, 10, [12] [13] [14] [15] [16] [17] [18] ) is the most important disadvantage of transplantation compared to conventional chemotherapy.
The relative effectiveness of different preparative regimens has been difficult to determine; many studies have been small and few meaningful comparisons between regimens have been performed. Bu has been extensively utilized in autologous and allogeneic transplantation in a variety of lymphohematopoietic disorders, 19, 20 however, only limited studies have been performed in NHL. 12, 14, 21, 22 Bu effectively eradicates normal lymphoid cells in animals 23 and humans, 24 although this occurs slowly. It is effective in the treatment of multiple myeloma, 25, 26 acute lymphoblastic leukemia, 27 and non-Hodgkin's 12, 14, 21, 22 and Hodgkin's 14, 20 lymphomas. We previously evaluated a preparative regimen of Bu 16 mg/kg and Cy 120 mg/kg (BuCy 2 ) as treatment for NHL. 14, 21 Its use, in this disease, is associated with a high incidence of severe hepatic veno-occlusive disease (VOD) and of treatment-related mortality. 14, 28, 29 When BuCy 2 is used as preparative therapy in NHL, mortality rates appear to be in the range of 10%; 12, 14, 22 similar to the incidence reported with other regimens. BuCy 2 is widely used and accepted as standard preparative therapy in NHL. 30 The BuCy 2 regimen was revised in the present study by lowering the Bu dose from 16 mg/kg to 14 mg/kg in the hope that severe hepatic VOD and transplant-related mortality would be decreased. Others have demonstrated decreased hepatotoxicity and improved safety with this lower dose of Bu. 26, 31 Etoposide was added in the hope of improving effectiveness without increasing the mortality rate substantially. The addition of etoposide to TBI/Cy 32, 33 and to BCNU/Cy 13 improves effectiveness in the treatment of NHL. We present here the results of a large biinstitutional study of Bu/etoposide/Cy in the treatment of patients with NHL.
Patients and methods

Patient selection
Between August 1992 and December 1998, 382 patients with NHL received a first autologous peripheral blood progenitor cell transplant following Bu, etoposide and Cy at The Arthur G James Cancer Hospital at The Ohio State University (OSU) or at the Cleveland Clinic Foundation (CCF). All patients who underwent transplantation according to protocol were included in the analysis. The protocol and consent forms were approved by the institutional review boards of each institution. All evaluations were based on data available as of 15 + cells/kg). Methodology of stem cell collection and cryopreservation has been previously described. 34 
Treatment regimen
All patients received a preparative regimen of Bu, etoposide and Cy. According to protocol, for patients at OSU, doses of all three drugs were based on the lower of the ideal body weight (IBW) or real body weight (RBW) unless the RBW exceeded IBW by 20%. In that case, an adjusted ideal body weight (AIBW), the IBW plus 25% of the difference between the IBW and RBW, was used. All patients at the CCF received Bu and Cy doses based on AIBW and etoposide based on RBW.
Bu was administered at a dose of 1 mg/kg orally every 6 h for 14 doses beginning 8 days prior to cell infusion. Phenytoin prophylaxis was administered prior to and during Bu administration. Etoposide, 50 mg/kg in an initial patient cohort, and then 60 mg/kg in a subsequent cohort, was initiated 2 h after completion of the Bu dose and was infused continually over 36 h. Cy 60 mg/kg was then administered intravenously over 1-2 h on each of 2 successive days, the last dose given approximately 48 h prior to cell infusion. G-CSF 5 g/kg was administered daily following transplantation until the neutrophil count reached 5000/l.
Toxicity
Regimen-related toxicity was graded according to criteria described by Bearman et al 35 and hepatic VOD severity according to McDonald et al. 29 
Statistical analysis
Univariate analyses of survival and event-free survival used the Kaplan-Meier product limit method 36 with logrank tests 37 of survival curves. Cox proportional hazards regression 38 was used in multivariate analyses to identify possible prognostic factors.
Results
Patient characteristics
The 382 patients in this study were aged 17-72 (median 49) years. Ninety-five patients had low-grade histology, 231 intermediate and 56 high-grade histology. Two hundred and eighty-eight patients received two or less courses of chemotherapy and 94 patients received three or more courses prior to transplantation. One hundred and twentyone patients had received prior radiation therapy. Patient characteristics are fully described in Table 1 .
Preparative therapy
One hundred and fifty-two patients received etoposide 50 mg/kg and 230 received 60 mg/kg. Accrual at each dose was specified in the protocol. In 108 patients, doses of all three drugs were based on the lower of the IBW or RBW. Twenty-six (obese) patients were dosed according to AIBW. Two hundred and forty-eight patients had BuCy doses based on AIBW and etoposide on RBW.
Hematopoietic recovery
No patients died before day 21; all were evaluated for hematopoietic recovery. Recovery to 500 neutrophils/l occurred at a median of 9 days post transplant (range 7-19 days) and platelet recovery to 20 000 at a median of 16 (range 8-55) days.
Toxicity
All patients developed grade I or greater RRT in at least one organ. Oral toxicity was most common with grade I or greater toxicity occurring in all but six patients. Grade III or IV toxicity occurred in at least one organ in 14 patients (3.7%). The most common severe toxicity was hepatic (six Table 1 Patient characteristics (n = 382) 
Cause of death
Ten patients (2.6%) patients died within 1 year of transplantation from treatment-related complications. Four died from respiratory failure, three from VOD, two from infection, and one from bleeding. Three of the seven patients who died of causes other than VOD, had severe VOD. Four patients developed myelodysplasia or acute myelogenous leukemia (AML) 1-5 years following transplantation. All died as a result.
Relapse and progression-free survival (PFS)
In all, 134 patients (35%) had persistent lymphoma or relapsed. Two hundred and thirty-two patients (61%) are progression-free survivors 0.5 years to 6.8 years (median 33 months) following transplantation. The estimated 3-year PFS for the entire group is 46.9% (95% CI 40.5-53.3%) ( Figure 1 ). Factors associated with poor PFS in multivariate analysis were elevated LDH (P Ͻ 0.0001), insensitivity to chemotherapy (P = 0.005), and intermediate/aggressive histology (P Ͻ 0.001) (Figure 2 ). Table 2 describes the results of multivariate analysis. For 156 patients who underwent transplantation in first sensitive relapse, PFS was 47.0% (95% CI, 37-57%) ( Figure 3 ). Patients with low-grade disease had a significantly better outcome (P = 0.04) among this group (56.4 ± 27.5% vs 43.7 ± 11.4%). Twenty-two patients (with high risk disease) transplanted in first CR had a 3-year PFS of 54.9% (95% CI, 31.4-78.4%).
Neither the dose of etoposide (50 mg/kg vs 60 mg/kg) nor the body weight parameter utilized for dose calculations correlated significantly with treatment-related mortality, relapse or PFS (P Ͼ 0.2). There was no correlation of obesity with toxicity or DFS (P Ͼ 0.2). 
Discussion
Severe hepatic VOD was the most common life-threatening toxicity with this novel regimen, developing in 11 patients (2.9%). This incidence represents a marked improvement compared to that reported with BuCy 2 14,29 and accounts in part for the lower mortality rate with this regimen. The treatment-related mortality rate in this large study was less than 3%, substantially lower than that reported for BuCy 2 12,14 and for several other standard regimens in NHL. 1, 3, 5, 8, 10, 13, [15] [16] [17] [18] The safety of the preparative regimen merits emphasis beyond its favorable impact on overall and PFS. Early mortality represents, for most patients and physicians, the chief disadvantage of transplantation compared to conventional therapy. As the safety of transplantation approaches that of conventional chemotherapy, the effectiveness of transplantation is no longer offset by this risk. Furthermore, it encourages the use of transplantation early in the course of disease where its use is most appropriate.
Delayed toxicity of preparative therapy also merits consideration. Radiation-containing regimens are associated with a high incidence of second malignancies. [39] [40] [41] [42] Treatment-associated myelodysplasia and AML have emerged as a frequent (estimated probability up to 20%) and lethal late complication of autotransplantation for lymphoma. TBI-containing preparative regimens significantly increase the risk of this complication. 41, 42 While follow-up in this study is insufficient to reach meaningful conclusions, a relatively low incidence of MDS and AML occurred, similar to prior experience with BuCy. 19 The effectiveness of this regimen appears superior to that of BuCy 2 , an accepted standard therapy in the treatment of NHL. In a recent study it compared favorably to BEAC in patients with low-grade lymphoma. 12 The results achieved in this trial are at least comparable to those achieved with other preparative regimens.
In this study, patients with low-grade lymphoma had a significantly better 3-year disease-free survival than did patients with more aggressive forms of lymphoma. Along with other studies, [6] [7] [8] [9] [10] [11] [12] it demonstrates sustained effectiveness of this treatment in patients with low-grade disease. This investigation did not attempt to determine the incidence of cure in patients with low-grade lymphoma. While some published studies suggest that the incidence of relapse is high, sustained disease-free survival, even without cure, might be a worthy reason for transplantation, especially when transplant-related mortality is low.
Similar to other studies, elevated LDH and chemotherapy sensitivity were found to have a significant adverse effect on prognosis. Older patient age was not a significant adverse prognostic factor. This treatment was safely administered in patients up to age 72.
No statistically significant difference between the different measures of body size used to calculate doses of drugs in the preparative regimen was detected. However, problems in dosing pertain predominantly to obese patients, all of whom (in this study) received BuCy dosed according to AIBW. Pharmacokinetic studies of Bu demonstrate that compared to IBW or RBW, AIBW minimizes differences in clearance among normal and obese patients, and is the appropriate measure of body size for dose calculations in all adults. 43 The body size parameter used for dose calculations should not vary between patients based on an artificial threshold, eg ABW Ͼ 120% RBW.
Institutions commonly dose BuCy on different body size parameters, without specific mention, even within single collaborative studies. 44, 45 It is unfortunate that interpretation of studies of BuCy is complicated by these variations in doses based on different measures of body size. The failure of most studies to even report the measure of body size used prevents meaningful comparisons of results. We recommend the use of AIBW for calculation of BuCy doses and mention of the parameter used to calculate doses in all publications.
Plasma levels of Bu affect hepatic VOD [46] [47] [48] [49] and other treatment-related toxicity, [47] [48] [49] as well as relapse. 49 We previously noted a high incidence of hepatic VOD and treatment-related toxicity following BuCy 2 in patients with NHL compared to patients with leukemia and attributed this, in part, to the extent and type of prior chemotherapy and radiation. 14 Gibbs et al 43 recently reported lower clearance of Bu in patients with NHL compared to those with CML and suggested that lowering the dose of Bu in patients with NHL would be prudent. The toxicity of Bu is related to steady-state levels, [46] [47] [48] [49] suggesting that a lowered dose at each administration would result in decreased hepatic toxicity. The clinical results of the present study suggest that truncating the course of therapy can also achieve this result.
Exposure to 4-hydroxyclophosphamide (HCY) is substantially greater following administration of Bu and is related to Bu exposure. 50 While hepatic VOD and other toxicity following BuCy is generally attributed to Bu, Cy is also hepatotoxic 51, 52 and contributes to other complications. 53 The lower toxicity seen in this study compared to prior studies of BuCy may be, in part, attributed to the lesser exposure to Bu and the more than 48 h interval between the last Bu dose and the first dose of Cy. This interval was recently identified as important in Bu's affect on Cy metabolism. 54 Prior regimens using Bu, etoposide and Cy, which have been associated with substantially greater toxicity, have not utilized a lower Bu exposure and prolonged interval between Bu and Cy. [55] [56] [57] The study did not demonstrate significant differences in outcome as a result of etoposide dose. However, the toxicity and mortality of this regimen was surprisingly low, minimizing the impact of the relatively small variations in etoposide dose. Longer follow-up is needed to adequately define the effect on relapse.
Bu, etoposide and Cy are a promising preparative regimen for autologous transplantation in patients with NHL. The results of this study are superior to those we have reported with BuCy 2 . The regimen has a low incidence of transplant-related mortality and appears to be associated with a low incidence of myelodysplasia and AML. This regimen is worthy of and requires further study in this disease as well as others in which BuCy 2 has proven effective. The recent availability of intravenous Bu offers the opportunity for further modification of Bu scheduling, which has been insufficiently studied, and the opportunity to further decrease the incidence of hepatic and other toxicity. 45 The Ohio State University for their compassionate and detailed work on our units. We would also like to thank the referring physicians for their trust in our care of their patients, and Norma Haas for preparing the manuscript.
